{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:14:38Z","timestamp":1790759678698,"version":"4.1.0"},"reference-count":14,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T00:00:00Z","timestamp":1702944000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009812","name":"Chinese Society of Clinical Oncology","doi-asserted-by":"publisher","award":["Y\u2010tongshu2021\/qn\u20100205"],"award-info":[{"award-number":["Y\u2010tongshu2021\/qn\u20100205"]}],"id":[{"id":"10.13039\/501100009812","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>Several studies have demonstrated the effectiveness of anti\u2010angiogenic drugs in combination with immune checkpoint inhibitors (ICIs) in patients with microsatellite stable (MSS) or mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC). However, whether combination radiotherapy (RT) can further improve the prognosis of mCRC patients after second\u2010line treatment remains to be explored.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Retrospective analysis of data from mCRC patients who received anti\u2010angiogenic targeted therapy (TT) and immunotherapy (IT) with or without RT after the failure of standard therapy. Progression\u2010free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), and safety were evaluated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 82 patients who received TT + IT were analyzed. For RT group (<jats:italic>n<\/jats:italic> = 42) versus NRT group (<jats:italic>n<\/jats:italic> = 40), ORR was 21.4% (9\/42) versus 5.0% (2\/40); DCR was 83.8% (35\/42) versus 65.0% (26\/40). Compared with NRT group, RT improved PFS (median: 5.0 vs. 3.6 months; <jats:italic>p<\/jats:italic> = 0.04) and OS (median: 15.2 vs. 7.2 months; <jats:italic>p<\/jats:italic> = 0.01). In addition, in the population receiving RT, the PFS of RT sequential\/simultaneous TT + IT was superior to TT + IT sequential RT (median: 7.1 vs. 6.2 vs. 3.5 months, <jats:italic>p<\/jats:italic> = 0.004). Multivariate analysis suggested RT was an independent prognostic factor for PFS and OS. No treatment\u2010related deaths were reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Compared with TT + IT, RT combined with TT + IT improved survival outcomes in MSS\/pMMR mCRC patients, with manageable toxicity. RT sequential\/simultaneous TT + IT treatment is expected to be the optimal strategy for MSS\/PMMR mCRC.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.6820","type":"journal-article","created":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T11:01:32Z","timestamp":1702983692000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy and safety of radiotherapy combined with anti\u2010angiogenic therapy and immune checkpoint inhibitors in <scp>MSS<\/scp>\/<scp>pMMR<\/scp> metastatic colorectal cancer"],"prefix":"10.1002","volume":"13","author":[{"given":"Menglan","family":"Zhai","sequence":"first","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College Huazhong University of Science and Technology  Wuhan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Queen Mary School, Medical Department Nanchang University  Nanchang Jiangxi China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haihong","family":"Wang","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College Huazhong University of Science and Technology  Wuhan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghua","family":"Ren","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College Huazhong University of Science and Technology  Wuhan China"},{"name":"Hubei Key Laboratory of Precision Radiation Oncology  Wuhan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College Huazhong University of Science and Technology  Wuhan China"},{"name":"Hubei Key Laboratory of Precision Radiation Oncology  Wuhan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjie","family":"Li","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College Huazhong University of Science and Technology  Wuhan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lichao","family":"Liu","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College Huazhong University of Science and Technology  Wuhan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisha","family":"Li","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College Huazhong University of Science and Technology  Wuhan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Radiology Union Hospital, Tongji Medical College, Huazhong University of Science and Technology  Wuhan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Radiology Union Hospital, Tongji Medical College, Huazhong University of Science and Technology  Wuhan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4018-3393","authenticated-orcid":false,"given":"Tao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College Huazhong University of Science and Technology  Wuhan China"},{"name":"Hubei Key Laboratory of Precision Radiation Oncology  Wuhan China"},{"name":"Institute of Radiation Oncology Union Hospital, Tongji Medical College, Huazhong University of Science and Technology  Wuhan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1733-5806","authenticated-orcid":false,"given":"Zhenyu","family":"Lin","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College Huazhong University of Science and Technology  Wuhan China"},{"name":"Hubei Key Laboratory of Precision Radiation Oncology  Wuhan China"},{"name":"Institute of Radiation Oncology Union Hospital, Tongji Medical College, Huazhong University of Science and Technology  Wuhan China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,12,19]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0504"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2022.100620"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2000463"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12226"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaa260"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.686621"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2023.07.001"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2022.02.009"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00752-5"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2018.06.001"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.992611"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1067036"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-019-0247-2"},{"key":"e_1_2_12_15_1","doi-asserted-by":"crossref","unstructured":"WangK ChenY ZhangZet\u00a0al.A Phase II Trial of Multisite Stereotactic Ablative Radiotherapy (SABR) Combined With Fruquintinib and Tislelizumab in Metastatic Colorectal Cancer.2022Available at:https:\/\/mp.weixin.qq.com\/s\/5uq_AGJS4eKuzVagpjLLdw","DOI":"10.1093\/gastro\/goad063"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.6820","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T10:30:54Z","timestamp":1714127454000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.6820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,19]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1002\/cam4.6820"],"URL":"https:\/\/doi.org\/10.1002\/cam4.6820","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,19]]},"assertion":[{"value":"2023-08-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e6820"}}